Business Description
Regen BioPharma Inc
NAICS : 325414
SIC : 2836
ISIN : US75886M3007
Total Employee Number:
1Description
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -20.41 | |||||
Debt-to-Equity | -0.15 | |||||
Debt-to-EBITDA | -0.92 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -143.25 | |||||
Beneish M-Score | -11.58 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -35.9 | |||||
3-Year EPS without NRI Growth Rate | 28.3 | |||||
3-Year FCF Growth Rate | 45.2 | |||||
3-Year Book Growth Rate | 49 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.96 | |||||
9-Day RSI | 46.36 | |||||
14-Day RSI | 47.3 | |||||
3-1 Month Momentum % | -37.5 | |||||
6-1 Month Momentum % | -87.5 | |||||
12-1 Month Momentum % | -99.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.05 | |||||
Quick Ratio | 0.05 | |||||
Days Sales Outstanding | 380.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -80.4 | |||||
Shareholder Yield % | -108 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -340.68 | |||||
Net Margin % | -502.54 | |||||
EBITDA Margin % | -413.14 | |||||
FCF Margin % | -188.21 | |||||
OCF Margin % | -188.56 | |||||
ROA % | -471.76 | |||||
ROIC % | -18.58 | |||||
3-Year ROIIC % | -0.05 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.04 | |||||
EV-to-EBIT | -1.1 | |||||
EV-to-EBITDA | -1.1 | |||||
EV-to-Revenue | 4.54 | |||||
EV-to-FCF | -2.42 | |||||
Price-to-GF-Value | 0.01 | |||||
Earnings Yield (Greenblatt) % | -90.91 | |||||
FCF Yield % | -264.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:RGBP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regen BioPharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.237 | ||
| EPS (TTM) ($) | -0.02 | ||
| Beta | -1.4878 | ||
| 3-Year Sharpe Ratio | -1.33 | ||
| 3-Year Sortino Ratio | -1.59 | ||
| Volatility % | 84.64 | ||
| 14-Day RSI | 47.3 | ||
| 14-Day ATR ($) | 0.000071 | ||
| 20-Day SMA ($) | 0.000118 | ||
| 12-1 Month Momentum % | -99.44 | ||
| 52-Week Range ($) | 0.00005 - 0.039 | ||
| Shares Outstanding (Mil) | 1,675.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regen BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regen BioPharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2027-02-12 | In 149 days | ||
| Annual report for 2026 | 2026-12-30 | In 105 days | ||
| General meeting for 2025 | 2026-09-23 | In 7 days | ||
| Third quarter earnings results for 2026 | 2026-08-17 | 0.00 (-50.00%) | ||
| Second quarter earnings results for 2026 | 2026-05-14 | 0.00 (+12.50%) | ||
| First quarter earnings results for 2026 | 2026-02-13 | 0.00 (-12.50%) | ||
| Annual report for 2025 | 2025-12-30 | 0.01 (-4.95%) | ||
| Emerging Growth Conference 88 | 2025-12-10 12:00 | 0.01 (-15.31%) | ||
| The Emerging Growth Conference | 2025-09-24 16:25 | 0.01 (-7.14%) | ||
| Third quarter earnings results for 2025 | 2025-08-11 | 0.04 (-3.38%) |
Show
Entries
Regen BioPharma Inc Frequently Asked Questions
What is Regen BioPharma Inc(RGBP)'s stock price today?
The current price of RGBP is $0.00. The 52 week high of RGBP is $0.04 and 52 week low is $0.00.
When is next earnings date of Regen BioPharma Inc(RGBP)?
The next earnings date of Regen BioPharma Inc(RGBP) is 2026-11-17 Est..
Does Regen BioPharma Inc(RGBP) pay dividends? If so, how much?
Regen BioPharma Inc(RGBP) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers